
Acalabrutinib demonstrated superior progression-free survival for r/r chronic lymphocytic leukaemia patients
Acalabrutinib, a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European…
Acalabrutinib, a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European…
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein…
The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed…